Vitamin E prevents buthionine sulfoximine-induced biochemical disorders in the rat.
Antioxidant therapy can improve the protection and metabolic activity of cells and tissues. In this study, the effect of vitamin E administration on buthionine sulfoximine (BSO)-induced glutathione (GSH) depletion in the rat lung and liver was investigated. Hepatic GSH was depleted by intraperitoneal administration of BSO (4 mmol kg(-1)), twice a day, for 30 days to rats. We also investigated whether the lung and liver mitochondrial GSH contents were influenced by BSO administration and whether an extracellular supply of vitamin E could prevent the changes caused by BSO-mediated GSH depletion. Glutathione levels in lung and liver tissues were depleted by 47% and 60%, respectively. Depletion of hepatic and pulmonary GSH in turn causes decline in the levels of mitochondrial GSH, leading to impaired antioxidant defence function of mitochondria. Both the cytosolic and mitochondrial glutathione disulfides (GSSG) were altered during BSO treatment, and led to drastic increase in GSSG/GSH redox status. One of the experimental groups was given vitamin E (65 mg (kg diet)(-1)) mixed with rat feed. The rats fed with vitamin E were found to have partially restored GSH levels in liver and lung, diminished levels of TBARS and minimized tissue damage. The current findings suggest that the impaired glutathione and glutathione-dependent enzyme status may be correlated with the elevated lipid peroxidation and mitochondrial membrane damage and that vitamin E therapy to the BSO-administered rats prevents the above changes. However, vitamin E did not have any effect on the activity of gamma-glutamyl cysteine synthetase (gamma-GCS).
Rajasekaran
Namakkal Soorappan
NS
Department of Zoology, University of Madras, Guindy Campus, Chennai, India.
Devaraj
Niranjali S
NS
Devaraj
Halagowder
H
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use*; D019328:Buthionine Sulfoximine / Q000009:adverse effects*; D005978:Glutathione / Q000172:deficiency / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D024502:alpha-Tocopherol / Q000378:metabolism / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D000975:Antioxidants; D017392:Thiobarbituric Acid Reactive Substances; D019328:Buthionine Sulfoximine; D005978:Glutathione; D024502:alpha-Tocopherol